Trevi Therapeutics, Inc. (TRVI) Stock: Seeing Gains In Today’s Session


Trevi Therapeutics, Inc. (TRVI) is gaining in the market today. The stock, one that is focused on the biotechnology industry, is presently trading at $3.69 after a move up of 1.18% so far in today’s session. As it relates to biotech stocks, there are a number of factors that have the ability to lead to gains in the market. News is one of the most common reasons for movement. Here are the recent headlines surrounding TRVI:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-08-19 12:08PM Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
Sep-05-19 04:05PM Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forum
Aug-12-19 04:05PM Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments
Aug-09-19 11:40AM Have Insiders Been Buying Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares?
Jun-13-19 04:09PM Trevi Therapeutics Announces First Quarter 2019 Financial Results and Recent Business Developments

Nonetheless, any time investors are making a decision to invest, prospective investors should take a look at much more than news, this is especially the case in the speculative biotech space. Here’s what’s happing when it comes to Trevi Therapeutics, Inc..

Performance Trends That We’ve Seen From TRVI

Although a move up on a single session, like what we’re seeing from Trevi Therapeutics, Inc. might make some investors jump for joy, a single session move alone should not be the basis of a decision to, or not to, invest in a stock. It is generally a good idea to look at trends experienced by the stock just a single trading day. As it relates to TRVI, here are the returns that investors have experienced:

  • Weekly – Throughout the past 7 days, TRVI has generated a change in price that amounts to 11.78%.
  • Past Month – The monthly returns from Trevi Therapeutics, Inc. comes to -22.50%.
  • Past 3 Months – Over the past quarter, the stock has produced a return on investment of -25.05%
  • Bi-Annually – Over the last 6 months, we’ve seen a change that amounts to -58.04% from the stock.
  • This Year So Far – Since the close of last year TRVI has produced a ROI of -53.83%.
  • Full Year – Lastly, throughout the last year, we have seen a change in the amount of 0 out of TRVI. Throughout this period of time, the stock has sold at a high price of -65.30% and a low price of 39.08%.

Ratios To Pay Attention To

Digging into a few ratios having to do with a company can provide prospective investors a view of just how risky and/or potentially profitable a pick might be. Here are a few of the important ratios to think about when digging into TRVI.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. As the short ratio goes higher, it shows that more investors have a belief that the stock is headed for declines. In general, biotech stocks can come with a higher short ratio. However, we tend to see a lot of short squeezes in the sector. Nonetheless, in relation to Trevi Therapeutics, Inc., it’s short ratio amounts to 1.62.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Basically, they measure whether or not a company can cover its debts when they mature using quick assets or current assets. In the biotechnology sector, companies rely heavily on the continuation of support from investors, these ratios can seem damning. However, several good picks in the biotech industry come with positive current and quick ratios. As it relates to TRVI, the quick and current ratios come to 10.50 and 10.50 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets owned by the company. In this case, the book to share value ratio comes in at 3.80.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the value of the company’s stock. Several clinical stage biotech companies struggle to keep cash on hand. So, if you’re interested in a biotechnology stock, this is an important ratio to consider. In this case, the cash to share value comes to 4.29.

Analyst Opinions Of Trevi Therapeutics, Inc.

Although it’s not a good idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a good idea to consider their analysis when validating your own when it comes to making an investment decision in the biotechnology sector. Here are the most recent moves that we’ve seen from analysts with regard to TRVI.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-03-19 Initiated SVB Leerink Outperform $14
Jun-03-19 Initiated Stifel Buy $20
Jun-03-19 Initiated Needham Buy $18
Jun-03-19 Initiated BMO Capital Markets Outperform $15

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in TRVI, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutions hold 86.60% of the company. However, it is important to consider that institutional ownership has seen a move in the amount of 0.08% over the last quarter.
  • Investors On The Inside – When it comes to insiders, insiders of the company currently hold 13.90% of the company. Insider ownership of the company has moved 0.00% over the last quarter.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 16.64M shares of Trevi Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, TRVI has a float of 16.50M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to TRVI, the short percent of the float is 0.13%.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.20. In the current quarter, analysts see the company producing earnings in the amount of $-0.48. Over the last 5 years, TRVI has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 3.30% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an AI, I am very dependent on my human counterparts. A human built me! While, my builders enabled me to learn on my own, it’s a lot simpler to learn when I receive feedback from human beings. At the bottom of this article, you’ll find a comment section. If you’d like for me dig into other information, change the way in which I communicate, take a look at data from a different perspective, or just about anything else, I want to know. To let me in on your thoughts consider leaving a comment below. I’ll process your comment and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here